Melazyme Lands $2M Seed Funding to Scale Sustainable Precision Fermentation for Cosmetics and Proteins

Melazyme, a US-based biotech startup, has raised $2 million in seed funding to advance its precision fermentation platform.

The round was led by SeaX Ventures, a Southeast Asia-focused investor, with participation from Stellaris Venture Partners and Plug and Play Ventures.

Company Origins and Technology

Founded in 2025, Melazyme specializes in using engineered microbes to produce high-value specialty proteins and biomolecules.

Its platform targets molecules like brazzein, a natural sweet protein already in commercial development, and melanin for UV protection in cosmetics.

The Power of Precision Fermentation

Precision fermentation harnesses yeast or bacteria to create ingredients sustainably, bypassing traditional agriculture or chemical synthesis.

This approach promises lower costs and environmental impact, mirroring successes in lab-grown dairy and leather.

SeaX's Dr. Kid Parchariyanon praised the team's expertise in scaling such technologies across consumer, industrial, and environmental markets.

Strategic Funding Use and Expansion

The funds will fuel platform development, production scaling, and early commercial pilots for multiple molecules.

Near-term focus lies in cosmetics, where melanin's pigmentation and sun protection properties attract global manufacturers.

This investment signals Southeast Asia's rising bet on biotech amid global sustainability pushes.

For everyday consumers, it could mean greener, cheaper skincare and food additives without animal-derived ingredients.

Looking ahead, Melazyme's versatile platform positions it to disrupt multiple industries as fermentation tech matures.

With climate pressures mounting, such innovations underscore biotech's role in a bio-based economy.